HR Execs on the Move

Terumo Medical Corporation

www.terumomedical.com

 
Terumo Medical Corporation (TMC), a leading medical device manufacturer employs approximately 700 people in offices throughout the United States, with its corporate headquarters located in Somerset, NJ.
  • Number of Employees: 100-250
  • Annual Revenue: $250-500 Million

Executives

Name Title Contact Details
Valentina Restrepo
Research And Development Engineer Intern Profile
John Barrett
Sr. Vice President Product Development, Engineering and Lifecycle Management Profile
Kristina Connelly
Director of Training Profile
Jeff Dobbs
Vice President - Human Resources Profile

Similar Companies

Bunnell

Bunnell is a Salt Lake City, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Apricus Biosciences Inc.

Apricus Biosciences Inc. is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in San Diego, CA. To find more information about Apricus Biosciences Inc., please visit www.apricusbio.com

AMD LASERS

AMD LASERS is a Indianapolis, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Northwest Medical Center

Northwest Medical Center, Inc. is a Margate, FL-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Kite Pharma

Kite Pharma, founded in 2009, is dedicated to the development and commercialization of novel cancer immunotherapy products designed to harness the power of a patient’s own immune system to fight tumor cells. Kite’s lead programs are in collaboration with the National Cancer Institute (NCI) and are being studied through the NCI’s Surgery Branch led by Steven A. Rosenberg, MD, PhD, who has pioneered immunotherapy approaches for cancer for more than two decades. This research has resulted in breakthrough clinical findings, including results from an NCI Phase 1/2a trial being presented at this year’s American Society of Hematology (ASH) Annual Meeting. Based on this progress and momentum, Kite plans to initiate a company-sponsored multicenter clinical program in aggressive non-Hodgkin’s lymphoma, with additional filings expected for other eACT™ products in diverse oncology indications.